Brought to you by
ECR 2018 / C-1501
Advanced renal cell carcinoma and the new targeted anticancer therapies: When the progression is not progression
Congress: ECR 2018
Poster No.: C-1501
Type: Educational Exhibit
Keywords: Cancer, Diagnostic procedure, CT, Abdomen
Authors: J. A. Fernández Gajardo1, P. Lopez Sala2, G. Unzue2, C. Saavedra Gutierrez2, J. Angarita Beltran2, N. Alonso Ordás2, N. Alberdi2, I. Rubio Marco2, R. Monreal2; 1Pamplona, Navarra/ES, 2Pamplona/ES
DOI:10.1594/ecr2018/C-1501

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65(1):5–29.
  2. Hirsch MS, Signoretti S, Dal Cin P. Adult renal cell carcinoma: a review of established entities from morphology to molecular genetics. Surg Pathol Clin 2015;8(4):587–621.
  3. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol 2013;37(10):1469–1489.
  4. Brufau BP, Cerqueda CS, Villalba LB, Izquierdo RS, González BM, Molina CN. Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT. RadioGraphics 2013;33(6): 1691–1716
  5. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008;26(1):127–131.
  6. Shinagare AB, Giardino AA, Jagannathan JP, Van den Abbeele AD, Ramaiya NH. Hereditary cancer syndromes: a radiologist’s perspective. AJR Am J Roentgenol 2011;197(6):W1001–W1007.
  7. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22(24):4991–5004.
  8. Shuin T, Kondo K, Torigoe S, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994;54(11):2852–2855.
  9. Figlin RA, Rathmell WK, Bloom J, eds. Renal cell carcinoma: translational biology, personalized medicine, and novel therapeutic targets. New York, NY: Springer Science & Business Media, 2012.
  10. Li L, Kaelin WG Jr. New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am 2011;25(4):667–686.
  11. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008;30(4):393–402.
  12. Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci 2006;36(3):283–293.
  13. Voss MH, Molina AM, Motzer RJ. mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am 2011;25(4):835–852.
  14. Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007;13(6):1757–1761.
  15. Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66(7):3381–3385.
  16. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006;24(35):5601–5608.
  17. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1803–1813.
  18. Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res(2017) 23(8):1920–8.
  19. Motzer R.J et al. (2017) Kidney cancer, version 2.2017. J Natl Compr Canc Netw.;15(6):804–834.
  20. Shinagare et al. Advanced Renal Cell Carcinoma: Role of the Radiologist in the Era of Precision Medicine. Radiology 2017 284:2, 333-351.
POSTER ACTIONS Add bookmark Contact presenter Send to a friend Download pdf
SHARE THIS POSTER
2 clicks for more privacy: On the first click the button will be activated and you can then share the poster with a second click.

This website uses cookies. Learn more